Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization grows 14.6% year over year
Q4 FY2025 depreciation & amortization of $181K rose 14.6% year over year. Over 3 fiscal years it compounded at -11.9% a year.
Context
- Depreciation & amortization amounted to 1100.0% of revenue in FY2025, up 1097.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 704K USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +2.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 704K | +6.7% |
| FY2024 | 2024-12-31 | 660K | -8.3% |
| FY2023 | 2023-12-31 | 720K | -30.2% |
| FY2022 | 2022-12-31 | 1.03M | +62.6% |
| FY2021 | 2021-12-31 | 634K | — |
Depreciation & Amortization vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.7% is the 3rd highest of 8, against a peer median of -3.9%.
- Depreciation & amortization amounts to 1100.0% of revenue for CNTB, versus a peer median of 185.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7M USD | -8.9% | -4.0% | 6.7% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.64M USD | +6.6% | +30.9% | — |
IMAImageneBio Inc | LTM Mar 2026 | $822K USD | +129.6% | +11.2% | — |
| FY2025 | $704K USD | +6.7% | -11.9% | 1100.0% | |
| LTM Mar 2026 | €392.86K EUR | -17.3% | -11.1% | 1339.4% | |
| LTM Mar 2026 | $167K USD | -73.0% | -39.9% | 2.3% | |
| LTM Mar 2026 | $48.3K USD | +290.5% | +20.6% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K USD | — | — | — |
| Peer median (excluding CNTB) | — | -3.9% | +6.3% | 185.5% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.